{
    "organizations": [],
    "uuid": "b7b3eab4bfee7a36458832527adc058837307a89",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fennec-says-phase-3-siopel-6-study/brief-fennec-says-phase-3-siopel-6-study-met-primary-endpoint-idUSASC09TK8",
    "ord_in_thread": 0,
    "title": "BRIEF-Fennec Says Phase 3 SIOPEL 6 Study Met Primary Endpoint",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26 (Reuters) - Fennec Pharmaceuticals Inc:\n* FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR ENDED DECEMBER 31, 2017 FINANCIAL RESULTS\n* PHASE 3 SIOPEL 6 STUDY MET PRIMARY ENDPOINT * FENNEC - SIOPEL 6 STUDY SHOWED ADDITION OF STS SIGNIFICANTLY REDUCES INCIDENCE OF CISPLATIN-INDUCED HEARING LOSS WITHOUT EVIDENCE OF TUMOR PROTECTION\n* QTRLY ‍LOSS PER SHARE $0.15​ * FENNEC - ‍BELIEVES CASH & CASH EQUIVALENTS ON HAND AS OF DEC 31, 2017 WILL BE SUFFICIENT TO FUND PLANNED COMMERCIAL LAUNCH OF PEDMARK (TM) IN H2 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-26T18:37:00.000+03:00",
    "crawled": "2018-03-27T11:37:13.020+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "fennec",
        "pharmaceutical",
        "inc",
        "fennec",
        "provides",
        "business",
        "update",
        "announces",
        "fiscal",
        "year",
        "ended",
        "december",
        "financial",
        "result",
        "phase",
        "siopel",
        "study",
        "met",
        "primary",
        "endpoint",
        "fennec",
        "siopel",
        "study",
        "showed",
        "addition",
        "sts",
        "significantly",
        "reduces",
        "incidence",
        "hearing",
        "loss",
        "without",
        "evidence",
        "tumor",
        "protection",
        "qtrly",
        "per",
        "share",
        "fennec",
        "cash",
        "cash",
        "equivalent",
        "hand",
        "dec",
        "sufficient",
        "fund",
        "planned",
        "commercial",
        "launch",
        "pedmark",
        "tm",
        "h2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}